CollabRx Leads Global Shift as Digital Healthcare Market Set to Reach $3.7 Billion by 2028 with Blockchain and AI
SAN FRANCISCO, Aug. 29, 2025 (GLOBE NEWSWIRE) -- CollabRx, Inc., a U.S.-based healthcare technology pioneer, is taking the lead in the global digital healthcare transformation. The industry is projected to grow from USD 1.3 billion in 2023 to USD 3.7 billion by 2028, at a compound annual growth rate (CAGR) of 23.2%, according to MarketsandMarkets. At the center of this growth are two breakthrough technologies - Blockchain and Artificial Intelligence (AI) - setting new global standards for security, transparency, and patient-first care.
Blockchain and AI: Transforming Global Healthcare
Blockchain technology ensures transparent and tamper-proof storage of medical records, enabling secure cross-border data sharing while protecting patient privacy. By eliminating fragmented data silos, Blockchain creates a seamless global flow of healthcare information that is both safe and efficient.
Meanwhile, AI is reshaping diagnostics and treatment by analyzing massive volumes of medical data. From early disease detection to personalized treatment planning, AI supports physicians in delivering more accurate and effective care. More importantly, it ushers in an era of personalized medicine, where treatment is tailored to each patient’s genetics, medical history, and drug responses.
Together, Blockchain and AI are not just technical tools but also a new healthcare philosophy - transparent, secure, and patient-first - reflecting the future of global digital healthcare.
CollabRx: A Pioneer in Blockchain and AI for Healthcare
One of the companies leading this global shift is CollabRx, Inc., a U.S.-based healthcare technology innovator. CollabRx leverages Blockchain, Web3, and AI to develop expert systems that assist physicians in identifying optimal treatment plans for molecular diseases, particularly cancer.
Speaking at the TingNect - Build For Billions event, Robert Pham, Asia Development Director of CollabRx, emphasized:
“We believe that the adoption of AI and Blockchain will help define the future standards of digital healthcare - a system where data is managed transparently, securely, and where patients truly stand at the center of care.”
CollabRx is also expanding its global partnerships, including a strategic collaboration with Trust Labs, a leading Web3 and Blockchain company, to build a comprehensive digital healthcare ecosystem.
The Future of Digital Healthcare
As Blockchain and AI continue to penetrate every layer of the healthcare system - from data management to patient care - the industry is moving closer to a future where high-quality, transparent, and personalized healthcare is accessible to people everywhere.
With its pioneering role, CollabRx is committed to driving innovation and building a trusted ecosystem that empowers physicians, protects patients, and accelerates the global adoption of digital healthcare solutions.
About CollabRx, Inc.
CollabRx, Inc. is a U.S.-based healthcare technology company specializing in the application of Blockchain, Web3, and AI to support physicians in clinical decision-making, with a strong focus on oncology and molecular diseases. Through global partnerships and cutting-edge innovation, CollabRx is dedicated to shaping the future of digital healthcare.
Media Contact:
CollabRx, Inc.
Contact Person: Robert Pham – Asia Development Director
Emai: contact@collabrx.com
Disclaimer: This press release is provided by CollabRx, Inc.. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. This content is for informational purposes only and should not be considered financial, investment, or trading advice. Investing involves significant risks, including the potential loss of capital. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility.
Legal Disclaimer: This media platform provides the content of this article on an "as-is" basis, without any warranties or representations of any kind, express or implied. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above.
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/40009f7b-af94-48aa-9142-ebea80bcb576
https://www.globenewswire.com/NewsRoom/AttachmentNg/e870a96d-6ed2-4df8-a16d-4a8fd1761a4b
Robert Pham, Asia Development Director of CollabRx
Robert Pham, Asia Development Director of CollabRx
Mr. Robert Pham, Asia Development Director of CollabRx
Mr. Robert Pham, Asia Development Director of CollabRx
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
